Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis
Portaccio, Emilio;Fonderico, Mattia;Iaffaldano, Pietro;Pastò, Luisa;Razzolini, Lorenzo;Bellinvia, Angelo;De Luca, Giovanna;Ragonese, Paolo;Patti, Francesco;Brescia Morra, Vincenzo;Cocco, Eleonora;Sola, Patrizia;Inglese, Matilde;Lus, Giacomo;Pozzilli, Carlo;Maimone, Davide;Lugaresi, Alessandra;Gazzola, Paola;Comi, Giancarlo;Pesci, Ilaria;Spitaleri, Daniele;Rezzonico, Marta;Vianello, Marika;Avolio, Carlo;Logullo, Francesco O;Granella, Franco;Salvetti, Marco;Zaffaroni, Mauro;Lucisano, Giuseppe;Filippi, Massimo;Trojano, Maria;Amato, Maria Pia
2022-01-01
Abstract
Except for ocrelizumab, treatment options in primary progressive multiple sclerosis (PPMS) are lacking.